Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Committee Upholds Negative Opinions On Cimzia, Rhucin Applications

This article was originally published in The Pink Sheet Daily

Executive Summary

Pharming will use new Rhucin trial data to support BLA, European appeal.

You may also be interested in...



UCB’s Cimzia Priced At Discount To Humira

Launch strategy for the anti-TNF in Crohn’s disease includes free trials, co-pay assistance, UCB says.

UCB’s Cimzia Priced At Discount To Humira

Launch strategy for the anti-TNF in Crohn’s disease includes free trials, co-pay assistance, UCB says.

Jerini’s Icatibant Falters in U.S., Wins In Europe

FDA rejects orphan drug for hereditary angioedema, paving way for rivals to gain an edge.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS067451

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel